Assenagon Asset Management
URGN icon

Assenagon Asset Management’s UroGen Pharma URGN Stock Holding History

Assenagon Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,047
Closed -$236K – 1362
2020
Q2 		$236K Buy
+9,047
New +$221K ﹤0.01% 1049
2019
Q3 		– Sell
-58,446
Closed -$2.1M – 1084
2019
Q2 		$2.1M Buy
58,446
+40,704
+229% +$1.5M 0.02% 514
2019
Q1 		$655K Buy
17,742
+8,033
+83% +$337K 0.01% 773
2018
Q4 		$418K Buy
+9,709
New +$437K ﹤0.01% 854

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management's URGN Position: Q3 2020 in Review

Assenagon Asset Management sold out of UroGen Pharma (URGN) in Q3 2020, closing a stake of 9,047 shares — an estimated $236K sold.

Assenagon Asset Management first reported a position in URGN in Q4 2018 and held it in 4 quarters. The position peaked at $2.1M in Q2 2019. 80 funds tracked by Wall St. Rank hold URGN as of Q3 2020.

  • Assenagon Asset Management reported no remaining UroGen Pharma position as of Q3 2020 after selling out during the quarter.
  • Assenagon Asset Management sold 9,047 UroGen Pharma shares in Q3 2020, an estimated $236K.
  • Assenagon Asset Management first reported a position in UroGen Pharma in Q4 2018 and held it in 4 quarters.
  • Assenagon Asset Management's UroGen Pharma position peaked at $2.1M in Q2 2019.
  • 80 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2020.

Based on Assenagon Asset Management's 13F filing for Q3 2020, filed 7 Oct 2020.